|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
CTG006392539 |
003 |
DE-627 |
005 |
20230629100644.0 |
007 |
cr uuu---uuuuu |
008 |
210507s2023 xx |||||o 00| ||eng c |
035 |
|
|
|a (DE-627)CTG006392539
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2017-000348-17-GB
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)CSL842_3001
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)2017-000348-17-BE
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
245 |
1 |
0 |
|a Efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care for the treatment of refractory antibody mediated rejection (AMR) in adult renal transplant recipients
|b A Double-blind, Randomized-Withdrawal, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Human Plasma-Derived C1-esterase Inhibitor as Add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients
|
264 |
|
1 |
|c 2023
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 12-05-2017, Last updated: 2023-06-29
|
650 |
|
4 |
|a Medical Condition: Refractory AMR in adult renal transplant participants MedDRA version: 20.0Level: PTClassification code 10023439Term: Kidney transplant rejectionSystem Organ Class: 10021428 - Immune system disorders;Therapeutic area: Body processes [G] - Immune system processes [G12]
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 3
|
650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 21. Juni
|
773 |
1 |
8 |
|g year:2023
|g day:21
|g month:06
|
856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-000348-17
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2023
|b 21
|c 06
|